[ad_1]
DUBLIN, December 24, 2021 / PRNewswire / – The “Global Rheumatoid Arthritis Market (2021 Edition) – Analysis by Drug Type (NSAIDs, DMARDs, Corticosteroids, Others), Treatment, Diagnosis, by Region, by Country: Market Overview and Forecast with the Impact of COVID-19 (2021-2026)) †the report was added to ResearchAndMarkets.com offer.
The Global Rheumatoid Arthritis Market Has Been Valued At $ 24.46 billion in the year 2020
Globally, the Rheumatoid Arthritis market is growing rapidly and the major factor driving the growth of Rheumatoid Arthritis is aging population. Additionally, some evidence suggests that people who smoke are at an increased risk of developing rheumatoid arthritis.
DMARD segment is expected to hold a significant share of the Rheumatoid Arthritis market due to the increasing prevalence of rheumatoid arthritis incidences across the world, the launch of therapeutic agents, and favorable reimbursement policies for high cost treatment products. . These are the main factors driving the growth of the market.
The Americas region has dominated the global Rheumatoid Arthritis market and dominated the industry in 2020 due to the presence of a large patient base and the availability of well-developed infrastructure, growing awareness of the treatment of diseases, growing geriatric population and high adoption of biopharmaceuticals for treatment.
There is also an increase in funds provided to academic research institutes and individual researchers, which is expected to drive the growth of the market. In addition, various initiatives of international organizations, such as WHO and NIH for the prevention and treatment of chronic disorders, such as cardiovascular disease, rheumatoid arthritis, and cancer are expected to facilitate the market growth.
The report tracks competitive developments, strategies, mergers and acquisitions, and new product development.
Companies analyzed in the report include
-
Merck KGaA
-
Sanofi
-
Eli Lilly Company
-
Amgen Inc
-
Bristol-Mayor Squibb
-
F. Hoffman-La Roche Ltée.
-
Johnson & johnson
-
Cipla
-
Pfizer
-
Galapagos SA
-
Gilead Sciences
Main topics covered:
1. Scope and methodology of the report
1. Scope and methodology of the report
1.1 Scope of the report
1.2 Research methodology
1.3 Executive summary
2. Strategic recommendations
3. Rheumatoid Arthritis Market: Product Outlook
4. Global Rheumatoid Arthritis Market: Sizing and Forecast
4.1 Global Rheumatoid Arthritis Market Size, by Value, Year 2016-2026
4.2 Impact of COVID-19 on the Global Rheumatoid Arthritis Market
5.Global Rheumatoid Arthritis Market Segmentation – By Drug Type, By Treatment, By Diagnosis
5.1 Global Rheumatoid Arthritis Market Competitive Scenario: By Drug Type
5.1.1 NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) Market Size and Forecast (2016-2026)
5.1.2 DMARD (Disease Modifying Antirheumatic Drug) Market Size and Forecast (2016-2026)
5.1.3 Corticosteroids Market Size and Forecast (2016-2026)
5.1.4 Others – Market Size and Forecast (2016-2026)
5.2 Global Rheumatoid Arthritis Market Competitive Scenario: By Treatment
5.2.1 Tendon Repair Market Size and Forecast (2016-2026)
5.2.2 Joint Merger Market Size and Forecast (2016-2026)
5.2.3 Joint Replacement Market Size and Forecast (2016-2026)
5.2.4 Others – Market Size and Forecast (2016-2026)
5.3 Global Rheumatoid Arthritis Market Competitive Scenario: By Diagnosis
5.3.1 CRP (Creative Protein Test) Market Size and Forecast (2016-2026)
5.3.2 ESR (Erythrocyte Sedimentation Rate) Market Size and Forecast (2016-2026)
5.3.3 Others – Market Size and Forecast (2016-2026)
6. Global Rheumatoid Arthritis Market: Regional Analysis
6.1 Global Rheumatoid Arthritis Market Competitive Scenario: By Region
7. Americas Rheumatoid Arthritis Market: Segmentation (By Drug Type, By Treatment, By Diagnosis)
7.1 Americas Rheumatoid Arthritis Market: Size and Forecast (2016-2026), by Value
7.2 Americas Rheumatoid Arthritis Market – Top Companies
7.3 Market segmentation by type of drug (DMARDs, NSAIDs, corticosteroids, others)
7.4 Market segmentation by treatment (tendon repair, joint fusion, joint replacement and others)
7.5 Market segmentation by diagnostic (CRP, ESR and others)
7.6 Americas Rheumatoid Arthritis Market: Analysis by Country
7.7 Americas Rheumatoid Arthritis Market Opportunity Chart – By Country, By Value, 2026
7.8 Americas Rheumatoid Arthritis Market Competitive Scenario: By Country
7.9 United States Rheumatoid Arthritis Market: Size and Forecast (2016-2026), by Value
7.10 US Rheumatoid Arthritis Market Segmentation – By Drug Type, Treatment, Diagnosis (2016-2026)
7.11 Canadian Rheumatoid Arthritis Market: Size and Forecast (2016-2026), by Value
7.12 Canadian Rheumatoid Arthritis Market Segmentation – By Drug Type, By Treatment, By Diagnosis (2016-2026)
8. European rheumatoid arthritis market: segmentation (by type of drug, by treatment, by diagnosis)
9. Asia Pacific Rheumatoid Arthritis Market Segmentation (By Drug Type, By Treatment, By Diagnosis)
10. Global Rheumatoid Arthritis Market Dynamics
10.1 Drivers
10.2 Constraints
10.3 Trends
11. Market attractiveness
11.1 Chart Global Rheumatoid Arthritis Market Market Attractiveness – By Drug Type, 2026
11.2 Chart Global Rheumatoid Arthritis Market Market Attractiveness – By Treatment, 2026
11.3 Chart Global Rheumatoid Arthritis Market Market Attractiveness – By Diagnosis, 2026
11.4 Chart Global Rheumatoid Arthritis Market Market Attractiveness – by Region, 2026
12. Competitive landscape
12.1 Product Pipeline of Major Rheumatoid Arthritis Companies
12.2 Market share analysis
13. Business analysis
For more information on this report, visit https://www.researchandmarkets.com/r/8lhpkq
Media contact:
Research and markets
Laura Wood, senior
[email protected]
For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900
US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716
SOURCE Research and Markets
[ad_2]
